Circulating tumor necrosis factor‐α, interleukin‐1β, and interleukin‐17A estimates increased major adverse cardiac event risk in acute myocardial infarction patients
Journal of Clinical Laboratory Analysis · 2023
DOI: 10.1002/jcla.24853 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2023. Verfasst von Jing Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, HanDan Central Hospital, Handan, China. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Myocardial Infarction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Research and Development Program of HanDan.
Abstract (Originalsprache)
Background
Inflammatory cytokines are implicated in the development of atherosclerosis and cardiomyocyte injury during acute myocardial infarction (AMI). This study aimed to investigate the correlation of eight common inflammatory cytokines with major adverse cardiac event (MACE) risk and further establish a prognostic model in AMI patients.
Methods
Serum samples of 210 AMI patients and 20 angina pectoris patients were, respectively, collected at admission, to detect tumor necrosis factor‐alpha (TNF‐α), interleukin (IL)‐1β, IL‐6, IL‐8, IL‐10, IL‐17A, vascular cell adhesion molecule‐1 (VCAM‐1), and intercellular adhesion molecule 1 (ICAM‐1) via enzyme‐linked immunosorbent assay.
Results
TNF‐α, IL‐6, IL‐8, IL‐17A, VCAM‐1, and ICAM‐1 were elevated (all p < 0.050); IL‐10 ( p = 0.009) was declined; IL‐1β ( p = 0.086) was not varied in AMI patients compared with angina pectoris patients. TNF‐α ( p = 0.008), IL‐17A ( p = 0.003), and VCAM‐1 ( p = 0.014) were elevated in patients with MACE occurrence compared to patients without MACE occurrence; meanwhile, they possessed a relatively good value for identifying MACE risk via receiver‐operating characteristic (ROC) analysis. Subsequent multivariate logistic regression analysis revealed that the independent risk factors for MACE contained TNF‐α (odds ratio (OR) = 1.038, p < 0.001), IL‐1β (OR = 1.705, p = 0.044), IL‐17A (OR = 1.021, p = 0.009), history of diabetes mellitus (OR = 4.188, p = 0.013), history of coronary heart disease (OR = 3.287, p = 0.042), and symptom‐to‐balloon time (OR = 1.064, p = 0.030), whose combination disclosed a satisfying prognostic value for MACE risk (area under the curve: 0.877, 95% CI: 0.817–0.936).
Conclusion
Elevated levels of serum TNF‐α, IL‐1β, and IL‐17A independently correlated with MACE risk in AMI patients, which perhaps provide novel auxiliary for AMI prognostic prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, HanDan Central Hospital, Handan, China.
- Department of General Surgery (Department of Plastic Surgery), Affiliated Hospital of Hebei University of Engineering, Handan, China.
- Emergency Department, Handan Central Hospital, Handan, China.
Förderung
- Science and Technology Research and Development Program of HanDan
Zitieren
APA
Guo, J., Hu, Z., Ren, L., Zhao, W., Zuo, R., Guo, S., Jia, C., & Gao, W. (2023). Circulating tumor necrosis factor‐α, interleukin‐1β, and interleukin‐17A estimates increased major adverse cardiac event risk in acute myocardial infarction patients. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.24853
Vancouver
Guo J, Hu Z, Ren L, Zhao W, Zuo R, Guo S, et al. Circulating tumor necrosis factor‐α, interleukin‐1β, and interleukin‐17A estimates increased major adverse cardiac event risk in acute myocardial infarction patients. Journal of Clinical Laboratory Analysis. 2023. doi:10.1002/jcla.24853
BibTeX
@article{Guo2023,
author = {Guo, Jing and Hu, Zhenfeng and Ren, Liang and Zhao, Weibo and Zuo, Ruijing and Guo, Shuang and Jia, Chaoguo and Gao, Wei},
title = {Circulating tumor necrosis factor‐α, interleukin‐1β, and interleukin‐17A estimates increased major adverse cardiac event risk in acute myocardial infarction patients},
journal = {Journal of Clinical Laboratory Analysis},
year = {2023},
doi = {10.1002/jcla.24853}
}
EUVIMED